Challenges in Psychedelic Drug Development and Regulatory Setbacks

This chapter explores the hurdles companies face in using psychedelics for mental health treatments, including the FDA's rejection of an MDMA-assisted therapy by Lycos Therapeutics. It also discusses the retraction of associated research papers, highlighting the difficulties in the evolving psychedelic drug development landscape.